Document Detail


Antithrombotic and thrombolytic therapies for acute myocardial infarction.
MedLine Citation:
PMID:  9048261     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Antithrombotic and thrombolytic therapies confer clear net benefits in the treatment of acute myocardial infarction. Antithrombotic therapy with aspirin yields conclusive reductions in vascular mortality as well as reinfarction and stroke, and should be administered to all patients with suspected acute myocardial infarction. There is presently no clear evidence of net benefits from adding either delayed subcutaneous or immediate intravenous heparin to an antithrombotic regimen of aspirin. Direct thrombin inhibitors have theoretical advantages over heparin as antithrombotic agents, but further data are needed from large-scale randomized trials to determine whether these agents confer net benefits when given in conjunction with aspirin. Thrombolytic therapy yields clear reductions in mortality and should be considered for all patients with suspected acute myocardial infarction presenting within 12 h of symptom onset. The differences in the efficacy, safety or ease of administration of the various thrombolytic agents are small compared with the substantial benefits that would result from the wider use and earlier administration of any of the available agents. More widespread use of antithrombotic and thrombolytic therapies for acute myocardial infarction could prevent tens of thousands of premature deaths annually in the USA alone, and hundreds of thousands worldwide.
Authors:
S L Godfried; J M Gaziano; C H Hennekens
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Journal of cardiovascular risk     Volume:  3     ISSN:  1350-6277     ISO Abbreviation:  J Cardiovasc Risk     Publication Date:  1996 Oct 
Date Detail:
Created Date:  1997-05-14     Completed Date:  1997-05-14     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  9436980     Medline TA:  J Cardiovasc Risk     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  453-7     Citation Subset:  IM    
Affiliation:
Division of Preventive Medicine, Brigham and Women's Hospital, Boston, MA 02215-1204, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anistreplase / therapeutic use
Aspirin / therapeutic use
Fibrinolytic Agents / therapeutic use*
Heparin / therapeutic use
Humans
Myocardial Infarction / drug therapy*,  mortality
Streptokinase / therapeutic use
Thrombolytic Therapy*
Chemical
Reg. No./Substance:
0/Fibrinolytic Agents; 50-78-2/Aspirin; 81669-57-0/Anistreplase; 9005-49-6/Heparin; EC 3.4.-/Streptokinase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Risk factors for stroke mortality in men and women: The Busselton Study.
Next Document:  Serum bilirubin and cardiovascular risk factors in a Chinese population.